statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This price move could be a signal that TGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

TG Therapeutics (TGTX, $14.77) price may climb as it broke lower Bollinger Band on Apr 01, 2024

This is a signal that TGTX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

TG Therapeutics (TGTX, $15.69) Stochastic Oscillator left the oversold zone on March 25, 2024

TG Therapeutics, Inc. (NASDAQ:TGTX  Get Free Report) Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction on Tuesday, March 12th. The shares were sold at...

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells $351,340.00 in Stock

This is a Bearish indicator signaling TGTX's price could decline from here. Traders may explore shorting the stock or put options...

TG Therapeutics (TGTX, $15.37) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 14, 2024

Director Laurence Charney Sells 22,000 Shares of TG Therapeutics Inc (TGTX)

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX  Get Free Report) dropped 3.9% on Friday . The stock traded as low as $17.11 and last traded at $17.30. Approximately 1,522,506 shares changed...

TG Therapeutics (NASDAQ:TGTX) Stock Price Down 3.9%

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI  (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

This is a signal that TGTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

TG Therapeutics (TGTX, $18) RSI Indicator left the overbought zone on March 07, 2024

TG Therapeutics, Inc. (NASDAQ:TGTX  Free Report)  Equities researchers at B. Riley increased their Q1 2024 EPS estimates for TG Therapeutics in a research report issued to clients and...

B. Riley Brokers Increase Earnings Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX  Free Report)  Stock analysts at HC Wainwright reduced their Q1 2024 EPS estimates for TG Therapeutics in a research report issued on Wednesday...

HC Wainwright Comments on TG Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TGTX)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Volume	291.00
52-Wk High	$35.67
52-Wk Low	$6.46

TGTX TG Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals